logo
welcome
Reuters

Reuters

GSK's RSV, Shingles vaccines show on-par immune response in joint trial

Reuters
Summary
Nutrition label

79% Informative

GSK said co-administration of its respiratory syncytial virus vaccine and shingles shot together generated the same immune response in a late-stage trial as separate adminstration of the vaccines.

RSV causes over 177,000 hospitalizations and 14,000 deaths in the United States annually .

GSK under CEO Emma Walmsley has focussed on vaccines and infectious diseases.

VR Score

89

Informative language

96

Neutral language

37

Article tone

formal

Language

English

Language complexity

74

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

medium-lived

External references

no external sources

Source diversity

no sources

Affiliate links

no affiliate links